ATC Group: G04BE08 Tadalafil

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G04BE08 in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G04 Urologicals
3 G04B Other urologicals, incl. antispasmodics
4 G04BE Drugs used in erectile dysfunction
5 G04BE08 Tadalafil

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 10 mg

Active ingredients in G04BE08

Active Ingredient Description
Tadalafil

Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The resulting vascular relaxation increases blood perfusion which may be the mechanism by which symptoms of benign prostatic hyperplasia are reduced.

Related product monographs

Title Information Source Document Type  
CIALIS 2.5 mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
CIALIS 5 mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
QUATOR Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
TALMANCO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
TRIPAN 20mg Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
TRIPAN 5mg Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Brazil (BR)

Canada (CA)

Croatia (HR)

Finland (FI)

Germany (DE)

Ireland (IE)

Italy (IT)

Japan (JP)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Singapore (SG)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.